Low diffusion capacity predicts poor prognosis in extensive stage small cell lung cancer : a single-center analysis of 10 years
© 2023. The Author(s)..
BACKGROUND: Poor pulmonary function and chronic obstructive pulmonary disease (COPD) are associated with poorer overall survival (OS) in non-small-cell lung cancer (NSCLC) patients. Few studies have investigated the association between pulmonary function and OS in small-cell lung cancer (SCLC) patients. We compared the clinical characteristics of extensive disease SCLC (ED-SCLC) with or without moderately impaired diffusion capacity for carbon monoxide (DLco) and investigated the factors associated with survival in ED-SCLC patients.
METHODS: This retrospective single-center study was performed between January 2011 and December 2020. Of the 307 SCLC patients who received cancer therapy during the study, 142 with ED-SCLC were analyzed. The patients were divided into DLco < 60% group and DLco ≥ 60% groups. OS and predictors of poor OS were analyzed.
RESULTS: The median OS of the 142 ED-SCLC patients was 9.3 months and the median age was 68 years. In total, 129 (90.8%) patients had a history of smoking, and 60 (42.3%) had COPD. Thirty-five (24.6%) patients were assigned to the DLco < 60% group. Multivariate analysis revealed that DLco < 60% (odds ratio [OR], 1.609; 95% confidence interval [CI], 1.062-2.437; P = 0.025), number of metastases (OR, 1.488; 95% CI, 1.262-1.756; P < 0.001), and < 4 cycles of first-line chemotherapy (OR, 3.793; 95% CI, 2.530-5.686; P < 0.001) were associated with poor OS. Forty (28.2%) patients received < 4 cycles of first-line chemotherapy; the most common reason for this was death (n = 22, 55%) from grade 4 febrile neutropenia (n = 15), infection (n = 5), or massive hemoptysis (n = 2). The DLco < 60% group had a shorter median OS than the DLco ≥ 60% group (10.6 ± 0.8 vs. 4.9 ± 0.9 months, P = 0.003).
CONCLUSIONS: In this study, approximately one quarter of the ED-SCLC patients had DLco < 60%. Low DLco (but not forced expiratory volume in 1 s or forced vital capacity), a large number of metastases, and < 4 cycles of first-line chemotherapy were independent risk factors for poor survival outcomes in patients with ED-SCLC.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:149 |
---|---|
Enthalten in: |
Journal of cancer research and clinical oncology - 149(2023), 10 vom: 15. Aug., Seite 7275-7283 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kim, Jee Seon [VerfasserIn] |
---|
Links: |
---|
Themen: |
Diffusion capacity (DLco) |
---|
Anmerkungen: |
Date Completed 31.07.2023 Date Revised 16.04.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1007/s00432-023-04686-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM354185462 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM354185462 | ||
003 | DE-627 | ||
005 | 20240416232217.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00432-023-04686-2 |2 doi | |
028 | 5 | 2 | |a pubmed24n1377.xml |
035 | |a (DE-627)NLM354185462 | ||
035 | |a (NLM)36912944 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kim, Jee Seon |e verfasserin |4 aut | |
245 | 1 | 0 | |a Low diffusion capacity predicts poor prognosis in extensive stage small cell lung cancer |b a single-center analysis of 10 years |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 31.07.2023 | ||
500 | |a Date Revised 16.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a BACKGROUND: Poor pulmonary function and chronic obstructive pulmonary disease (COPD) are associated with poorer overall survival (OS) in non-small-cell lung cancer (NSCLC) patients. Few studies have investigated the association between pulmonary function and OS in small-cell lung cancer (SCLC) patients. We compared the clinical characteristics of extensive disease SCLC (ED-SCLC) with or without moderately impaired diffusion capacity for carbon monoxide (DLco) and investigated the factors associated with survival in ED-SCLC patients | ||
520 | |a METHODS: This retrospective single-center study was performed between January 2011 and December 2020. Of the 307 SCLC patients who received cancer therapy during the study, 142 with ED-SCLC were analyzed. The patients were divided into DLco < 60% group and DLco ≥ 60% groups. OS and predictors of poor OS were analyzed | ||
520 | |a RESULTS: The median OS of the 142 ED-SCLC patients was 9.3 months and the median age was 68 years. In total, 129 (90.8%) patients had a history of smoking, and 60 (42.3%) had COPD. Thirty-five (24.6%) patients were assigned to the DLco < 60% group. Multivariate analysis revealed that DLco < 60% (odds ratio [OR], 1.609; 95% confidence interval [CI], 1.062-2.437; P = 0.025), number of metastases (OR, 1.488; 95% CI, 1.262-1.756; P < 0.001), and < 4 cycles of first-line chemotherapy (OR, 3.793; 95% CI, 2.530-5.686; P < 0.001) were associated with poor OS. Forty (28.2%) patients received < 4 cycles of first-line chemotherapy; the most common reason for this was death (n = 22, 55%) from grade 4 febrile neutropenia (n = 15), infection (n = 5), or massive hemoptysis (n = 2). The DLco < 60% group had a shorter median OS than the DLco ≥ 60% group (10.6 ± 0.8 vs. 4.9 ± 0.9 months, P = 0.003) | ||
520 | |a CONCLUSIONS: In this study, approximately one quarter of the ED-SCLC patients had DLco < 60%. Low DLco (but not forced expiratory volume in 1 s or forced vital capacity), a large number of metastases, and < 4 cycles of first-line chemotherapy were independent risk factors for poor survival outcomes in patients with ED-SCLC | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Diffusion capacity (DLco) | |
650 | 4 | |a Prognosis | |
650 | 4 | |a Small-cell lung cancer (SCLC) | |
700 | 1 | |a Kim, Eun Ji |e verfasserin |4 aut | |
700 | 1 | |a Jang, Jong Geol |e verfasserin |4 aut | |
700 | 1 | |a Hong, Kyung Soo |e verfasserin |4 aut | |
700 | 1 | |a Ahn, June Hong |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of cancer research and clinical oncology |d 1981 |g 149(2023), 10 vom: 15. Aug., Seite 7275-7283 |w (DE-627)NLM000394610 |x 1432-1335 |7 nnns |
773 | 1 | 8 | |g volume:149 |g year:2023 |g number:10 |g day:15 |g month:08 |g pages:7275-7283 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00432-023-04686-2 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 149 |j 2023 |e 10 |b 15 |c 08 |h 7275-7283 |